NASDAQ$EWTX
Edgewise Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Edgewise Therapeutics reported financial results for the third quarter of 2022 and recent business highlights.
Edgewise Therapeutics reported a net loss of $17.5 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $365 million as of September 30, 2022. They also completed an upsized underwritten public offering of common stock, resulting in net proceeds of $129 million.
- Announced positive 6-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD).
- Advanced CANYON Phase 2 trial in BMD and initiated LYNX Phase 2 trial in Duchenne muscular dystrophy (DMD).
- Completed a successful financing to continue to drive muscular dystrophy programs through clinical development.
- Reported cash, cash equivalents and marketable securities of $365 million as of September 30, 2022.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$0
Forward guidance
The company plans to continue advancing its clinical trials and preclinical research programs, particularly focusing on EDG-5506 and EDG-002.
Tailwinds
- Advancing CANYON Phase 2 clinical trial of EDG-5506 in individuals with BMD.
- Initiated LYNX Phase 2 clinical trial of EDG-5506 in children with DMD.
- Advancing the EDG-002 program, focused on identifying cardiac muscle modulators.
- Plans to initiate IND-enabling studies in 2022 for EDG-002 program.
- Observed decreases in biomarkers of muscle damage and improvements in NSAA in ARCH trial with EDG-5506.
Headwinds
- Potential for product candidates to cause serious adverse events.
- Uncertainties regarding the timing, progress, and results of clinical trials.
- Dependence on raising additional funding to continue business and product development plans.
- Risk of negative impacts from the COVID-19 pandemic on operations.
- Potential for clinical trial results to differ from preclinical, interim, or expected results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro